Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RebOx: Crossover, Double-blind Phase 2 Study of Fixed-dose Reboxetine + Oxybutynin in Obstructive Sleep Apnea
2019-004917-15Phase 2Terminated
- Sponsor
- Istituto Auxologico Italiano
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing AD128 fixed-dose reboxetine + oxybutynin with Placebo (2 arms). Primary endpoint: Percentage change in Apnea Hypopnea Index (AHI) from baseline between groups. Started Jan 2021; status: terminated.
02
Drugs
reboxetineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2019-004917-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004917-15.